Unknown

Dataset Information

0

The iron(III)-adriamycin complex inhibits cytochrome c oxidase before its inactivation.


ABSTRACT: Cytochrome c oxidase was found to be competitively inhibited by a complex formed between Fe3+ and the cardiotoxic antitumour drug adriamycin (doxorubicin) with an inhibition constant, Ki, of 12 microM. This competitive inhibition precedes the slower Fe3+-adriamycin induced inactivation of cytochrome c oxidase. In strong contrast with this result, free adriamycin was not observed to either inhibit or inactivate cytochrome c oxidase (Ki greater than 3 mM). Since, typically, polycations are known to inhibit cytochrome c oxidase, the competitive inhibition displayed by the Fe3+-adriamycin complex may also result from its polycationic character. Cytochrome c oxidase was also inhibited by pentan-1-ol (Ki 13 mM), and kinetic studies carried out in the presence of both inhibitors demonstrated that the Fe3+-adriamycin complex and pentan-1-ol are mutually exclusive inhibitors of cytochrome c oxidase. The inhibitor pentan-1-ol was also effective in preventing the slow inactivation of cytochrome c oxidase induced by Fe3+-adriamycin, presumably by blocking its binding to the enzyme. It is postulated that the slow inactivation of cytochrome c oxidase occurs when reactive radical species are produced while the Fe3+-adriamycin is complexed to cytochrome c oxidase in an enzyme-inhibitor complex. The Fe3+-adriamycin-induced inactivation of cytochrome c oxidase may be, in part, responsible for the cardiotoxicity of adriamycin.

SUBMITTER: Hasinoff BB 

PROVIDER: S-EPMC1148930 | biostudies-other | 1988 Mar

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC1133711 | biostudies-other
| S-EPMC6004266 | biostudies-literature
| S-EPMC7159913 | biostudies-literature
2020-10-07 | GSE159080 | GEO
2016-01-01 | GSE57073 | GEO
2016-01-01 | GSE57048 | GEO
| S-EPMC5286356 | biostudies-literature
| S-EPMC1146609 | biostudies-other
| S-EPMC1264671 | biostudies-other
| S-EPMC3754557 | biostudies-literature